POSTER PRESENTATION



Open Access

Disturbance of HDL apolipoprotein AI metabolism in severe hyperlipidemic and lipodystrophic HIV patients on a protease inhibitor treatment

Khadija Ouguerram^{*}, Yassine Zair, Stéphanie Billon, Michel krempf

From 16th International Symposium on HIV and Emerging Infectious Diseases Marseille, France. 24-26 March 2010

Background

The aim of this study was to characterize the metabolic abnormalities resulting in low HDL apolipoprotein AI (HDL-AI) levels in lipodystrophy HIV infected patients during protease inhibitor therapy.

Methods

Seven HIV infected patients, normolipidemic with no lipodystrophy (group A) and seven hyperlipidemic with lipodystrophy (group B) were studied. Patients are on protease inhibitors since at least six months. Patients were underwent *in vivo* kinetics of HDL-AI using a 14 h primed constant infusion of $[5,5,5,^2H_3]$ leucine. Kinetic data were analyzed by monocompartmental model using SAMII program to drive metabolic parameters (FCR, Fractional Catabolic Rate, and APR, Absolute Catabolic Rate).

Results

Subjects in group B showed significantly higher plasma triglycerides (p < 0.05). HDL cholesterol and apolipoprotein AI (apoAI) were significantly (P < 0.05) lower in group B compared to group A. HDL are more enriched in triglycerides in group B compared to group A (P < 0.005). Kinetic study showed no change of fractional catabolic rate between two groups but significantly (P < 0.05) lower APR in group B compared to group A.

Discussion

These results showed that the hypertriglyceridemia and low HDL level associated with lipodystrophy in HIV infected patients during treatment is related essentially

* Correspondence: khadija.ouguerram@univ-nantes.fr INSERM U915, Nantes, France



Published: 11 May 2010

doi:10.1186/1742-4690-7-S1-P90 Cite this article as: Ouguerram *et al.*: Disturbance of HDL apolipoprotein Al metabolism in severe hyperlipidemic and lipodystrophic HIV patients on a protease inhibitor treatment. *Retrovirology* 2010 7(Suppl 1):P90.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit

